结构特征和在的毒性预测的降解杂质的roxadustat
Rupali Mahajan1, Sanjeev Kumar2, Ramulu Parupalli2
1Department of Pharmaceutical Analysis, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, India.
Journal of pharmaceutical and biomedical analysis
|June 15, 2023
概括
在慢性病中治疗贫血的Roxadustat在酸性,性和光线条件下降解. 一个关键的杂质DP-4通过多种降解途径形成,并且由于其亚齐里丁结构,显示出潜在的毒性.
科学领域:
- 制药化学 制药化学 制药化学
- 分析化学 分析化学
- 药品安全 药品安全
背景情况:
- 罗沙杜沙特是第一种被批准用于治疗与慢性病相关的贫血的药物.
- 了解药物降解对于确保药品的质量和安全至关重要.
- 强制降解研究对于预测潜在的药物分解产物至关重要.
研究的目的:
- 在各种压力条件下调查roxadustat的降解概况.
- 为了识别和描述roxadustat的降解产品 (DPs).
- 评估roxadustat及其DP的潜在毒性.
主要方法:
- 根据ICH指南,强制降解roxadustat.
- 使用逆相HPLC和LC-Q-TOF/MS进行DP的分离和识别.
- 使用NMR光谱学对主要DPs (DP-4和DP-5) 的结构阐明.
- 在毒性评估 (致癌性,致变性,致性,皮肤敏感性) 和分子对接研究中.
主要成果:
- 确定了9种降解产品 (DP).
- 在热和氧化应激下,Roxadustat表现出稳定性,但在酸性,基性和光解条件下不稳定.
- 确定DP-4是性水解,中性水解和光解中常见的杂质.
- DP-4,在化学上 (1a-methyl-6-oxo-3-phenoxy-1,1a,6,6a-tetrahydroindeno [1,2-b]阿齐里丁-6a-carbonyl) 甘氨酸,具有阿齐里丁部分,引发了毒性问题.
- 在 silico 研究表明DPs与蛋白质的潜在毒性相互作用.
结论:
- 在酸性,基本性和光分解性条件下,Roxadustat的稳定性受到损害.
- 常见的杂质DP-4,其亚齐里丁结构,需要进一步的毒理学研究.
- 对roxadustat的降解产品进行全面的表征对于其安全使用至关重要.
相关概念视频
Structure-Activity Relationships and Drug Design
800
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
800
Factors Affecting Dissolution: Drug Permeability, Stability and Stereochemistry
235
Orally administered drugs primarily enter the systemic circulation via passive diffusion through the intestinal membranes. The drug's absorption is influenced by drug stability in the gastrointestinal GI tract, membrane permeability, the surface area available for absorption, luminal drug concentration, and residence time in the lumen. Drug permeability can be enhanced by adjusting the lipophilicity, polarity, or molecular size of the drug, promoting its passive transport across intestinal...
235
Mutagenicity and Carcinogenicity
1.3K
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
1.3K


